GLPwatch
Papers (10588)
Page 166 of 177, ranked by citation count.
- Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss.
- Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.
- Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density.
- Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.
- 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.
- Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
- Exploring Adults' Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study.
- Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations.
- Real-world experience of semaglutide 2.4 mg in the US: a retrospective analysis of profiles, satisfaction, and treatment patterns in people with obesity and overweight.
- Pharmaceutical Approval Update.
- The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
- Injections vs. Scalpels: Where Do Surgery and GLP-1's Align in Modern Obesity treatment?
- Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.
- Developing <sup>68</sup>Ga-Labeled Exendin(9-39) Derivatives for PET Imaging of Insulinomas.
- Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
- Liraglutide as First-Line Therapy for Type 2 Diabetics With Post-COVID-19 Fatigue Syndrome and Executive Function Deficits.
- Negative effects of semaglutide on bone in obese mice.
- Tirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide.
- Liraglutide improves cognitive function by reducing amyloid-beta peptide accumulation and inhibiting inflammation in 5 × FAD mice.
- The role of dulaglutide in the treatment of alcohol use disorder: a case report.
- Oral Delivery of Liraglutide Formulated with PLGA for Sustained Obesity Management.
- Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review.
- Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service.
- Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.
- The use of GLP-1 receptor agonists and subsequent risk of nicotine-related events: a cross- sectional study.
- Severe diabetic ketoacidosis associated with insulin dose reduction after tirzepatide initiation.
- Emulating the LEADER trial in China: a regulatory science case study on non-interventional research.
- Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy.
- Semaglutide vs Tirzepatide Dosages for Weight Loss-Reply.
- Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.
- Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report.
- Correction: Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.
- Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.
- Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Is it time to reassess the role of myocardial metabolic modulation for the treatment of heart failure?
- Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk.
- Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.
- National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss.
- No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.
- The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
- THE EFFECT OF EXENATIDE THERAPY IN PREVIOUSLY INSULIN-TREATED TYPE 2 DIABETIC PATIENTS.
- Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
- [Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBYII study (observations lasting 24 months)].
- Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Response to "Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis". Response to related letter.
- Drugs for type 2 diabetes.
- Mo-Rubbing abdominal improves metabolic homeostasis in type 2 diabetes mellitus mice via a jejunum-specific GLP1-dependent mechanism.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
- A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.
- In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
- Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin.
- Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying.
- Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
- A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa.
- From Glycemic Control to Weight-Centered Therapy: A Paradigm Shift in Type 2 Diabetes and Its Public Health Promise.
- Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane.